Real-world safety and tolerability of intravenous edaravone in patients with amyotrophic lateral sclerosis
Treatment discontinuation was primarily related to ALS disease progression/death, rather than safety or tolerability. This study representative of real-world patients with ALS suggests that edaravone showed consistent safety and tolerability profiles with previous studies.
Authors
- Malgorzata Ciepielewska
- Polina Da Silva
- Agessandro Abrahão (ORCID: https://orcid.org/0000-0003-1142-2842)
- Lorne Zinman
Institutions
- Sunnybrook Health Science Centre (CA)
- Mitsubishi Corporation (United States) (US)
- University of Toronto (CA)
Publication Details
- Journal
- Neurodegenerative Disease Management
- Published
- 2025-08-29
- DOI
- https://doi.org/10.1080/17582024.2025.2552610
- Primary Topic
- Amyotrophic Lateral Sclerosis Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00